Mineralys Therapeutics (MLYS) Change in Accured Expenses (2022 - 2026)

Mineralys Therapeutics has disclosed Change in Accured Expenses across 5 years of filings, most recently posting -$402000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$402000.0, up 74.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 127.16% YoY), and the FY2025 annual result was $427000.0, down 89.74% from the prior year.
• Change in Accured Expenses came in at -$402000.0 for Q1 2026 at Mineralys Therapeutics, up from -$8.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.5 million in Q2 2024 to a low of -$16.7 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $864000.0 (2022), against an average of $565588.2.
• Peak annual rise in Change in Accured Expenses reached 2627.14% in 2023, while the deepest fall reached 465.15% in 2023.
• Mineralys Therapeutics' Change in Accured Expenses stood at $846000.0 in 2022, then plunged by 461.82% to -$3.1 million in 2023, then sank by 444.72% to -$16.7 million in 2024, then jumped by 51.24% to -$8.1 million in 2025, then jumped by 95.06% to -$402000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$402000.0 (Q1 2026), -$8.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.